Discoverer of the Klotho Gene and Pioneer in Longevity and Disease Prevention Dr. Makoto Kuro-o Joins Scientific Advisory Board of ADvantage Therapeutics BOCA RATON, Fla. and VIENNA, Austria, Feb. 05, 2024 (GLOBE NEWSWIRE) -- ADvantage Therapeutics, a pioneer in developing therapies for neurodegenerative conditions by addressing the biology of aging,...

Klogenix’ pioneering research on age-related diseases and longevity gene Klotho finds new home at ADvantage Therapeutics, Inc. BOSTON, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Klogenix LLC (“Klogenix” or “the Company”) is pleased to announce that its intellectual property portfolio has been acquired by ADvantage Therapeutics, Inc....

ADvantage Therapeutics Welcomes Esteemed Expert in Alzheimer’s Disease and Klotho Protein, Carmela Abraham, Ph.D. as Chief Science Officer ADvantage Therapeutics appoints Dr. Carmela Abraham as Chief Science Officer

ADvantage Therapeutics Secures Approvals for Clinical Trial of AD04™ in Alzheimer’s Disease Treatment in Poland, Bulgaria, and Slovakia MIAMI, June 20, 2023 (GLOBE NEWSWIRE) -- ADvantage Therapeutics, Inc. (“ADvantage” or “the Company”), a pioneer in developing therapies for neurodegenerative conditions with a focus on Alzheimer’s...

MHRA Grants ADvantage Therapeutics Innovative Licensing and Access Pathway (ILAP) Designation for Novel Lead Product AD04™ for Phase 2b Trial in Alzheimer’s Disease MIAMI, April 05, 2023 (GLOBE NEWSWIRE) -- ADvantage Therapeutics, Inc. (“ADvantage” or “the Company”), which is developing therapies to treat neurodegenerative conditions with a central focus on...